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Aspergillus spp. are agents of a broad-spectrum of diseases among humans. Their
growing resistance to azoles, the cornerstone in the management of human aspergillosis,
is a worrisome problem around the world. Considering lack of data from Portugal on
this topic, particularly from the northern region, a retrospective surveillance study was
planned to assess frequency of cryptic Aspergillus species and azoles resistance. A
total of 227 clinical isolates, mainly from the respiratory tract (92.1%), collected from
three hospitals serving a population of about three million people, were studied for
their epidemiology and antifungal susceptibility patterns determined by the E.DEF.9.3
protocol of EUCAST. Employing molecular methods, seven Aspergillus complexes were
identified; Aspergillus fumigatus sensu stricto was the most frequent isolate (86.7%). A
7.5% prevalence of cryptic species was found; A. welwitschiae (A. niger complex-3.1%)
and A. lentulus (A. fumigatus complex-2.2%) were the most frequent. Amongst cryptic
species, it was found a percentage of resistance to voriconazole, posaconazole and
isavuconazole of 47.1, 82.4, and 100%, respectively. Five A. fumigatus sensu stricto
showed pan-azole resistance. Sequencing their cyp51A gene revealed the presence
of one isolate with TR46/Y121F/T289A mutation and two isolates with TR34/L98H
mutation. This study emphasizes the need to identify strains to the species level and
to evaluate their antifungal susceptibility in all human originated Aspergillus spp. isolates,
particularly those from invasive aspergillosis.
Keywords: Aspergillus spp., molecular identification, cryptic species, antifungal susceptibility, azole-resistant
A. fumigatus, cyp51A gene
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INTRODUCTION
Aspergillus fumigatus is the leading cause of human aspergillosis,
a mold infection that affects immunocompetent and particularly
immunocompromised patients. It manifests as a broad-spectrum
of diseases including aspergilloma, allergic bronchopulmonary
aspergillosis (ABPA), chronic pulmonary aspergillosis (CPA),
and invasive aspergillosis (IA), the most critical clinical picture.
In the last two decades, other non-A. fumigatus namely
A. flavus, A. terreus, and A. niger and cryptic species have been
isolated with increased frequency as causative agents (Lass-Flörl
et al., 2005; Krishnan et al., 2009; Alastruey-Izquierdo et al., 2012;
Steinbach et al., 2012). Such change in epidemiology has been
attributed to the increase in number of the immunocompromised
populations, advances in detection, identification of fungal
pathogens and the selective pressure caused by the extensive use
of broad-spectrum antifungal agents (Richardson and Lass-Flörl,
2008; Alastruey-Izquierdo et al., 2012).
The high diversity of the involved species, their antifungal
susceptibility patterns and the severity of the pathology
require fast and reliable methods for identification. In the
genomic era, molecular techniques became indispensable tools to
complement macroscopic and microscopic exam. Methods that
use the internal transcribed spacer (ITS), the β-tubulin and the
calmodulin regions, are of utmost importance to discern between
cryptic species, considered as members of the same complex and,
therefore, exhibiting almost indistinguishable morphological
properties (Peterson, 2012). Moreover, accurate identification at
the species level is crucial, as the emergence of cryptic species is
associated with specific patterns of antifungal susceptibility that
influence patient management strategies and treatment outcomes
(Balajee et al., 2007; Richardson and Lass-Flörl, 2008).
The cornerstone in the management of human aspergillosis
is azole treatment. Voriconazole (VCZ) is recommended as
the primary agent for IA or CPA, and alternative therapies
are isavuconazole (ICZ), liposomal amphotericin B (L-AMB)
and anidulafungin (ANI); posaconazole (PCZ) and VCZ are
also recommended for prophylaxis. For treatment of ABPA,
itraconazole (ITZ) is the first choice and VCZ and PCZ
are the second ones (Patterson et al., 2016). Also recently,
(Ullmann et al., 2018) published an extensive and detailed
article regarding diagnosis and management of aspergillosis,
summarizing recommendations of ESCMID, ECMM and ERS.
However, since the 90’s, reports of azole resistance in Aspergillus
spp., particularly A. fumigatus-complex, became more frequent
and now extends to the six continents (Mosquera and Denning,
2002; Howard et al., 2009; Van der Linden et al., 2015; Meis
et al., 2016). Several resistance mechanisms have been reported
in A. fumigatus strains, being mutations in the cyp51A gene one
of them (Vermeulen et al., 2012). The presence of TR34/L98H
mutation has been documented since 2007, and more recently,
the emerging TR46/Y121F/T289A mutant has been founded in
some countries (Verweij et al., 2007; Vermeulen et al., 2012;
Meis et al., 2016). Two possible ways for resistance acquisition
to azoles are recognized: “in vivo,” as consequence of azole
treatment for long periods and associated to a single mutation;
“de novo,” that seems to occur due to the widespread use of
demethylation inhibitors in agriculture and frequently associated
to a combination of a tendem repeat (TR) in the promoter
region of cyp51A and amino acid mutation(s) (Hagiwara et al.,
2016; Meis et al., 2016; Garcia-Rubio et al., 2017). Thus,
antifungal susceptibility testing of clinical Aspergillus isolates is
an important source of information in order to avoid therapeutic
failures.
In the clinical setting, an important issue is the presence
of cryptic species and the emergence of drug resistant
Aspergillus strains. Thus, the purpose of the present retrospective
epidemiological work was to analyse the distribution and
characterize the species of Aspergillus collected from clinical
setting in order to evaluate the presence of cryptic species, their
susceptibility patterns to antifungal drugs, and the emergence
of resistant strains, which are still unknown in Portugal,
particularly in the northern region. In addition, we investigated
the underlying resistance molecular mechanisms of A. fumigatus
strains.
MATERIALS AND METHODS
Sample Collection
A total of 227 Aspergillus clinical strains isolated between January
2010 and March 2016, from biological samples belonging to 207
patients with proven or probable infections or colonization, were
studied. They were admitted to the Centro Hospitalar do Porto
(HSP1) and Centro Hospitalar São João (HSP2), two tertiary
teaching hospitals, and Instituto Português de Oncologia do
Porto (HSP3), a hemato-oncological hospital; all of them located
within 10 km of distance from each other and serve a population
of three million people in north of Portugal.
Strains Identification: Morphological and
Molecular Methods
The strains, preserved in 20% Sabouraud broth-glycerol
at −80◦C, were grown on Sabouraud dextrose agar (SDA)
for 3–4 days at 35◦C in aerobic conditions. Morphological
identification was performed using standard microbiological
methods (De Hoog et al., 2001). The macroscopic features
and the microscopic morphology were considered. For
molecular identification at species level, the International
Society for Human and Animal Mycology-sponsored Aspergillus
Working Group recommendations were followed: amplification
of a portion of the β-tubulin gene using primers Bt2a
(5
′
-GGTAACCAAATCGGTGCTGCTTTC-3
′
) and Bt2b
(5
′
-ACCCTCAGTGTAGTGACCCTTGGC-3
′
) (Glass and
Donaldson, 1995). For some isolates, amplification of a portion
of calmodulin gene was performed additionally, using CL1
(5
′
-GA(GA)T(AT)CAAGGAGGCCTTCTC-3
′
) and CL2A
(5
′
-TTTTTGCATCATGAGTTGGAC-3
′
) primers (O’Donnell
et al., 2000; Balajee et al., 2007). PCR reactions were performed
using a direct DNA amplification kit, KAPA3G Plant PCR
Kit R© (KAPABIOSYSTEMS, Boston, USA). Briefly, one loop
of each fungal isolate was collected from 3 to 5 day’s cultures
in SDA and suspended in 100 µL of ultrapure water. PCR was
carried out in a 25 µL volume containing 2xKAPA3G Plant
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PCR Buffer (containing MgCl2 and dNTPs); an additional
0.5mM MgCl2; 0.3µM of each primer, and 0.5 Units of
Taq DNA polymerase (KAPA3G Plant DNA Polymerase).
Amplifications were running on a thermal cycler (Bio-Rad,
T100TM Thermal Cycler, California, USA) comprising an initial
denaturation step at 95◦C/15min followed by 40 cycles of
amplification (denaturation at 95◦C/20 s, annealing at 58◦C/15 s
and extension at 72◦C/min) and a final extension step at
72◦C/1min. A non-template negative control was included
in each amplification reaction. Positive PCR products were
purified using the GRS PCR & Gel Band Purification Kit (Grisp,
Porto, Portugal), according to the manufacturer’s instructions,
and sent to sequencing in both directions with the primers
used for amplification. Sequences obtained were manually
verified by MEGA7 software package and aligned using the
CLUSTALW algorithm. Afterwards, sequences were compared
with GenBank and CBS-KNAW Fungal Biodiversity Centre
databases. Identifications were based on database rankings and
only similarity values ≥99% were considered. The nucleotide
sequence representative of each identified species was deposited
in the GenBank database (accession numbers from KY696642-47
and KY696649-52).
Antifungal Susceptibility Testing
The 227 isolates were tested for in vitro antifungal susceptibility
using the broth microdilution method as recommended by the
protocol E.DEF9.3 of European Committee on Antimicrobial
Susceptibility Testing (EUCAST) (EUCAST-E.DEF 9.3)1. The
reference powders of amphotericin B (AMB, Sigma-Aldrich),
L-AMB (Gilead), ANI (Pfizer), caspofungin (CAS, Merck),
ITZ (Sigma-Aldrich), VCZ (Pfizer), PCZ (Fluka, Sigma-
Aldrich), and ICZ (Basilea Pharmaceutica) were tested with
a final concentration of 0.032-16 mg/L. Minimal inhibitory
concentrations (MICs) for AMB, L-AMB, and azoles, and
minimal effective concentrations (MECs) for ANI and CAS
were assessed. Quality control was assured using the strains
recommended by EUCAST: Candida krusei ATCC6258 and A.
fumigatus ATCC204305.
Considering the clinical breakpoints (CBPs) and
epidemiological cut-offs (ECOFFs), available on EUCAST
website (2017), was assessed the presence of resistant (R) and
non-wild type (NWT) strains, respectively. For all Aspergillus
species without CBPs or ECOFFs, were adopted the values
established for A. fumigatus.
PCR Amplification and Sequencing of
A. fumigatus Sensu stricto cyp51A Gene
For pan-azoles resistant A. fumigatus isolates (HSP3-115, HSP3-
32, HSP2-18, HSP3-111, HSP1-6) and for three A. fumigatus
isolate resistant to ITZ and PCZ (HSP2-67; HSP3-13; HSP3-
22) the molecular identification of resistance mechanism was
performed in the cyp51A gene. Moreover, one randomly A.
fumigatus isolate without resistance to azoles (HSP2-12) was also
analyzed. All isolates were previous identified as A. fumigatus
1EUCAST DEFINITIVE DOCUMENT E.DEF 9.3. Method for the determination
of broth dilution minimum inhibitory concentrations of antifungal agents for
conidia forming molds. December 2015.
by sequencing of part of the β-tubulin gene. The sequencing
of cyp51A gene and its promotor were obtained, after DNA
isolation, using a set of primers, PA-7/PA-5 and P450-A1/P450-
A2 (Mellado et al., 2001; Diaz-Guerra et al., 2003). The PCR
conditions were performed on the thermal cycler, comprising
an initial denaturation step at 95◦C/15min followed by 35
cycles of amplification (denaturation at 95◦C/30 s, annealing
at 60◦C/45 s and extension at 72◦C/1min, for PA-7/PA-5;
denaturation at 95◦C/30 s, annealing at 58◦C/45 s and extension
at 72◦C/5min, for P450-A1/P450-A2) and a final extension step
at 72◦C/1min. A non-template negative control was included
in each amplification reaction. Positive PCR products were
purified using the purification kit previously described. The
sequencing was done with a set of primers PA-7/PA-5, P450-
A2, cyp51AR3, cyp51AR2 (Mellado et al., 2001; Diaz-Guerra
et al., 2003; Prigitano et al., 2014) and a home-designed primer,
5’-GCAGTATGGCGATATCTTCACTT-3’. Sequences obtained
were compared with the sequence under accession number
AF338659 in GenBank, as wild type reference, in order to find
out the mutations. The nucleotide sequence of each A. fumigatus
isolate studied was deposited in the GenBank database (accession
numbers fromMH231594-MH231601 and MH040305).
RESULTS
227 clinical isolates of Aspergillus were collected from 207
patients, who included 114 males and 93 females averaging
57.9 years-old (6 months-95 years). The characteristics of each
isolate, such as gender, age at the time of sample, diagnostic,
collection date, sample source and the molecular identification
are presented as Supplementary Material (Table S1). Considering
the diagnosis, the most prevalent underlying condition were
hemato-oncological (23.2%), oncological (17.4%), lung disease
(15.9%), and organs solid transplant (7.2%); most samples
(92.1%) were isolated from the respiratory tract (Table S1).
Using morphological methods, six Aspergillus complexes were
identified, whereas the molecular characterization revealed seven
complexes. One isolate wasmorphologically identified only to the
genus level, but molecular methods identified it as A. sydowii.
Moreover, one misidentification at species complex level was
found: morphologically characterized as A. fumigatus whilst
molecular methods identified as A. nidulans.
A. fumigatus complex was found to be the most prevalent
(86.7%), which is consistent with previous reports (Balajee et al.,
2009; Lortholary et al., 2011; Steinbach et al., 2012). Also in
agreement with published data (Krishnan et al., 2009; Alastruey-
Izquierdo et al., 2012), we observed that the second most
prevalent complex was A. flavus (6.2%) followed by A. niger
(3.5%) and A. terreus complexes (1.8%).
With the use of β-tubulin sequencing, recognized as a suitable
molecular taxonomic target, we were able to identify fungal
species within a complex (Balajee et al., 2007; Peterson, 2012).
7.5% of isolates were identified as cryptic species: A. lentulus,
A. thermomutatus, A. felis, A. welwitschiae, A. pseudodeflectus,
and A. sydowii. Among them, A. welwitschiae (A. niger complex-
3.1%) and A. lentulus (A. fumigatus complex-2.2%) were the
most frequent. Less frequently A. thermomutatus and A. felis
(A. fumigatus complex-0.4% each one); A. sydowii (A. versicolor
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TABLE 1 | MICs/MECs (mg/L) range, geometric mean (GM) and values distribution of the eight antifungals, according EUCAST protocol.
Species (n◦ of isolates) Drug Range GM ≤0.032 0.064 0.125 0.25 0.5 1 2 4 8 ≥16
A. fumigatus (190) AMB 0.25–2 1.07 1 29 131 29
L-AMB 0.25–2 0.58 28 125 34 3
ANI 0.032–0.5 0.19 35 27 54 43 31
CAS 0.032–1 0.31 1 24 31 55 77 2
ITZ 0.25–16 1.49 5 50 90 37 3 5
VCZ 0.25–16 0.77 36 96 52 1 3 1 1
PCZ 0.032–16 0.34 20 21 30 90 21 6 1 1
ICZ 0.5–16 2.32 1 42 113 31 3
A. lentulus (5) AMB 8–16 11.20 3 2
L-AMB 16–16 16 5
ANI 0.125–0.5 0.30 2 1 2
CAS 0.5–2 0.90 3 1 1
ITZ 16–16 16 5
VCZ 2–16 6 1 3 1
PCZ 0.5–16 4.30 1 1 2 1
ICZ 16–16 16 5
A. felis (1) AMB 2 NA 1
L-AMB 4 NA 1
ANI 0.5 NA 1
CAS 0.5 NA 1
ITZ 8 NA 1
VCZ 4 NA 1
PCZ 0.25 NA 1
ICZ 4 NA 1
A. thermomutatus (1) AMB 1 NA 1
L-AMB 0.5 NA 1
ANI 0.25 NA 1
CAS 0.25 NA 1
ITZ 16 NA 1
VCZ 8 NA 1
PCZ 1 NA 1
ICZ 4 NA 1
A. flavus/oryzae (14) AMB 1–4 2.43 4 5 5
L-AMB 0.5–16 5.57 2 3 3 1 2 3
ANI 0.032–16 1.33 1 1 4 6 1 1
CAS 0.064–8 0.86 4 3 6 1
ITZ 0.5–16 2.50 4 3 5 1 1
VCZ 1–16 2.79 5 7 1 1
PCZ 0.25–2 0.84 5 1 6 2
ICZ 2–16 8 2 3 6 3
A. welwitschiae (7) AMB 0.5–1 0.79 3 4
L-AMB 0.125–1 0.41 1 3 2 1
ANI 0.064–0.5 0.19 2 2 2 1
CAS 0.25–0.5 0.39 3 4
ITZ 1–16 4.86 2 2 1 1 1
VCZ 0.5–1 0.71 4 3
PCZ 0.125–2 0.77 1 1 2 2 1
ICZ 2–8 4.57 2 3 2
(Continued)
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TABLE 1 | Continued
Species (n◦ of isolates) Drug Range GM ≤0.032 0.064 0.125 0.25 0.5 1 2 4 8 ≥16
A. niger (1) AMB 1 NA 1
L-AMB 0.25 NA 1
ANI 0.5 NA 1
CAS 0.5 NA 1
ITZ 2 NA 1
VCZ 1 NA 1
PCZ 0.5 NA 1
ICZ 4 NA 1
A. terreus (4) AMB 4–4 4 4
L-AMB 4–4 4 4
ANI 0.032–0.064 0.05 1 3
CAS 0.25–0.5 0.31 3 1
ITZ 0.25–0.5 0.38 2 2
VCZ 0.5–1 0.88 1 3
PCZ 0.064–0.25 0.17 1 1 2
ICZ 2–4 3 2 2
A. pseudodeflectus (2) AMB 2–2 2 2
L-AMB 0.5–1 0.75 1 1
ANI 1–2 1.50 1 1
CAS 8–8 8 2
ITZ 16–16 16 2
VCZ 16–16 16 2
PCZ 16–16 16 2
ICZ 16–16 16 2
A. nidulans (1) AMB 2 NA 1
L-AMB 1 NA 1
ANI 0.5 NA 1
CAS 0.5 NA 1
ITZ 1 NA 1
VCZ 0.25 NA 1
PCZ 0.5 NA 1
ICZ 1 NA 1
A. sydowii (1) AMB 2 NA 1
L-AMB 2 NA 1
ANI 0.125 NA 1
CAS 0.125 NA 1
ITZ 16 NA 1
VCZ 1 NA 1
PCZ 1 NA 1
ICZ 8 NA 1
AMB, amphotericin B; L-AMB, liposomal amphotericin B; ANI, anidulafungin; CAS, caspofungin; ITZ, itraconazole; VCZ, voriconazole; PCZ, posaconazole; ICZ, isavuconazole.
complex-0.4%); A. pseudodeflectus (A. ustus complex-0.9%) were
isolated.
MIC values for AMB, L-AMB and the four azoles (ITZ,
VCZ, PCZ, and ICZ), and MEC values for ANI and CAS were
determined for all isolates. Their range, geometric mean and
MICs/MECs distributions are displayed in Table 1. In Table 2
are shown the number and percentage of resistant and NWT
Aspergillus spp. vs. antifungal drugs, classified using the recently
proposed interpretive CBPs and ECOFFs. For ANI andCAS there
are not CBPs or ECOFFs established.
Eight azole-resistant A. fumigatus sensu stricto isolates were
studied. Mutations in the cyp51A gene were found in six; the
TR34/L98H and TR46/Y121F/T289A mutations, related with
resistance to several azoles, were found in three isolates, showing
a pan-azole resistance profile. Moreover, other mutations,
F46Y/M172V/N248T/D255E/E427K, were found in other three
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TABLE 2 | Number and percentage of resistant and non-wild type isolates of Aspergillus spp. to amphotericin B and four azoles.
AMB L-AMB ITZ VCZ PCZ ICZ
Species (n) R (%)
CBP>2
NWT
(%)
R (%)
CBP>2
NWT (%) R (%)
CBP>2
NWT (%)
ECOFFa
R (%)
CBP>2
NWT (%)
ECOFFb
R (%)
CBP>0.25
NWT (%) R (%)
CBP>1/
0.25#
NWT(%)
ECOFFc
A. fumigatus
(190)
0 NA 0 NA 8
(4.2)
45
(23.7)
5
(2.6)
6
(3.2)
29
(15.3)
NA 147
(77.4)
34
(17.9)
A. lentulus
(5)
5
(100)
NA 5
(100)
NA 5
(100)
5
(100)
4
(80)
5
(100)
5
(100)
NA 5
(100)
5
(100)
A. felis
(1)
0 NA 1
(100)
NA 1
(100)
1
(100)
1
(100)
1
(100)
0 NA 1
(100)
1
(100)
A. thermomutatus
(1)
0 NA 0 NA 1
(100)
1
(100)
1
(100)
1
(100)
1
(100)
NA 1
(100)
1
(100)
A. flavus/A. oryzae
(14)
5
(35.7)
NA 6
(42.9)
NA 2
(14.3)
7
(50)
2
(14.3)
2
(14.3)
9
(64.3)
NA 14
(100)
12
(85.7)
A. welwitschiae
(7)
0 NA 0 NA 3
(42.9)
5
(71.4)
0 0 5
(71.4)
NA 7
(100)
5
(71.4)
A. niger
(1)
0 NA 0 NA 0 0 0 0 1
(100)
NA 1
(100)
0
A. terreus
(4)
4
(100)
NA 4
(100)
NA 0 0 0 0 0 NA 4
(100)
4
(100)
A. pseudodeflectus
(2)
0 NA 0 NA 2
(100)
2
(100)
2
(100)
2
(100)
2
(100)
NA 2
(100)
2
(100)
A. nidulans
(1)
0 NA 0 NA 0 0 0 0 1
(100)
NA 1#
(100)
1
(100)
A. sydowii
(1)
0 NA 0 NA 1
(100)
1
(100)
0 0 1
(100)
NA 1
(100)
1
(100)
R, Resistant; NWT, non-wild type; NA, not applicable. AMB, amphotericin B; L-AMB, liposomal amphotericin B; ITZ, itraconazole; VCZ, voriconazole; PCZ, posaconazole; ICZ,
isavuconazole. CBP and ECOFF units—mg/L.
aECOFF values for A. niger−4, A. terreus−0.5, A. fumigatus and other species−1.
bECOFF values for A. flavus, A. terreus and A. niger−2, A. fumigatus and other species−1.
cECOFF values for A. niger−4, A. terreus−1, A. nidulans−0.25, A. fumigatus and other species−2.
azole-resistant A. fumigatus strains and no mutations were
observed in two of the isolates (Table 3).
DISCUSSION
Among filamentous fungi, Aspergillus spp. are described as the
most important agents of severe opportunistic infections and
the genus Aspergillus encompasses different clinically relevant
complexes: A. fumigatus complex, A. flavus complex, A. terreus
complex, A. ustus complex and A. nidulans complex. In the
present work, 227 clinical Aspergillus isolates were identified to
verify their species distribution and estimate the prevalence of
cryptic species in clinical setting.
Like in previous reports, in the present study A. fumigatus
complex was the most frequently isolated. However, regional
differences in the prevalence of these species have been reported:
A. flavus was described as the second most common Aspergillus
in medical centers of United States (Balajee et al., 2009), Europe
(Alastruey-Izquierdo et al., 2013), Brazil (Negri et al., 2014), and
regions with dry weather and/or arid conditions, as the Middle
East (Krishnan et al., 2009); A. terreus was reported as the second
most prevalent in Austria (Lackner et al., 2016); A. niger was
second in Korea (Heo et al., 2015).
Apart from the identification of the species, these results
raise the issue of the cryptic species prevalence in the clinical
setting. Although precisely unknown, several reports indicate a
frequency of 10–19%, which is slightly higher than the 7.5% of
the present research and might be related to the origin of clinical
samples, geographical differences or the underlying diseases
(Alastruey-Izquierdo et al., 2013; Negri et al., 2014; Sabino et al.,
2015).
In clinical settings, an important issue is the susceptibility
patterns to antifungal drugs. This applies mainly to cryptic
species, frequently reported as resistant, notably to azoles, which
emphasize the relevance of their identification and susceptibility
testing (Balajee et al., 2007; Alastruey-Izquierdo et al., 2013;
Negri et al., 2014; Heo et al., 2015; Lamoth, 2016). However,
also important the susceptibility testing for A. fumigatus sensu
stricto, the most frequently isolated, considering the emergence
of resistant strains.
For amphotericin, A. lenlutus, A. terreus, A. felis and 5 of 14
A. flavus/A. oryzae isolates showed high MIC values, and were
categorized as resistant according to the CBPs. Considering the
present and previous reported intrinsic resistance or variable
susceptibility of these species (Van Der Linden et al., 2011) the
therapy with AMB may not be a wise treatment option. AMB
and L-AMB showed MIC values≤2 mg/L for all the A. fumigatus
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TABLE 3 | Cyp51A mutations and azoles MICs by EUCAST to A. fumigatus isolates.
Cyp51A Mutations MIC (mg/L)/EUCAST
A. fumigatus isolates TR Codon Codon Codon Codon Codon Codon Codon Codon ITZ VCZ PCZ ICZ
46 98 121 172 248 255 289 427
HSP3-115 – F46Y – – M172V – E427K 4 8 4 4
HSP3-32 TR34 – L98H – – – – ≥16 4 0.5 4
HSP2-18 TR34 – L98H – – – – ≥16 4 1 ≥16
HSP3-111 TR46 – – Y121F – T289A – ≥16 ≥16 ≥16 ≥16
HSP1-6 – – – – – – – ≥16 4 1 ≥16
HSP3-13 – F46Y – – M172V N248T D255E – E427K 4 0.5 1 4
HSP3-22 – F46Y – – M172V – – – E427K 4 0.5 1 4
HSP2-67 – – – – – – – ≥16 1 0.5 2
HSP2-12* – – – – - – – 0.5 0.25 0.064 4
ITZ, itraconazole; VCZ, voriconazole; PCZ, posaconazole; ICZ, isavuconazole. *Not resistant strain. TR-tendem repeat.
sensu stricto isolates (190), suggesting overtime stability of AMB
susceptibility on this species. The continuous surveillance of
Aspergillus spp. susceptibility to AMB may properly address this
issue.
Regarding ANI and CAS only 1.3 and 3.1% of the isolates
showedMEC values higher than 0.5 mg/L, respectively. Although
CBPs are not available, the MECs were in general lower for
ANI than for CAS and particularly for ANI vs. A. fumigatus
and their cryptic species, with none value higher than 0.5 mg/L.
These observations corroborate ANI utilization on A. fumigatus
infections, in associations with azoles and/or amphotericin,
as recommended by Infectious Diseases Society of America
(Patterson et al., 2016).
In general, the azoles’ MICs for A. fumigatus sensu stricto
obtained in this study were higher than previously reported
(Perkhofer et al., 2009; Pfaller et al., 2011; Alastruey-Izquierdo
et al., 2013; Astvad et al., 2017). However, most of the isolates
were susceptible: 95.8% to ITZ, 97.4% to VCZ and 84.7% to
PCZ. Although PCZ showed crude lower MICs, these were
higher in isolates from the hemato-oncological hospital (21 of
the 29 isolates resistant to PCZ, 72.4%), where it is regularly
used as prophylactic treatment. Surprisingly, ICZ, a recently
introduced antifungal drug, revealed high MIC values. Most of
the isolates (59.4%) showed a MIC of 2 mg/L, being categorized
as resistant, and 17.9% showed MICs >2 mg/L and were
classified as NWT. Etest (data not showed) confirmed these
high MIC values and similar results were reported by Arendrup
et al. (2017). However, recently, Astvad et al. presented a
prevalence of 13.7% of NWT strains to ICZ on a selection of
211 A. fumigatus isolates from years 2012-2014 (Astvad et al.,
2017). Our prevalence of 17.9%, although higher, may reflect a
longer period of evaluation (2010 to March 2016) in a distinct
geography. Meanwhile, a recent study indicated that when A.
fumigatus isolates have MIC = 2 mg/L the treatment of infected
patients may still be successful with high doses ICZ (Buil et al.,
2018).
Regarding the cryptic species A. lentulus, A. felis,
A. thermomutatus, A. pseudodeflectus and A. sydowii, almost
all showed a resistance phenotype to all azoles tested (47.1%
to VCZ, 82.4% to PCZ, and 100% to ICZ), which agrees with
the literature (Balajee et al., 2007; Richardson and Lass-Flörl,
2008). Exceptions were one isolate of A. lentulus categorized as
intermediate to VCZ, A. felis susceptible to PCZ and A. sydowii
susceptible to VCZ.
The emergence of A. fumigatus with azole-resistant
phenotypes has been reported worldwide, resistance being
frequently associated with cyp51A gene mutations (Verweij et al.,
2007; Vermeulen et al., 2012; Meis et al., 2016). Considering
mutations’ acquisition origin, two routes were established in
the last years; environmental, due to the use of azole drugs
in agricultural practice; and patient-acquired, due to long
periods of azole treatment (Meis et al., 2016; Garcia-Rubio et al.,
2017).
Mutations in the cyp51A gene were found in six of the
eight azole-resistant A. fumigatus sensu stricto isolates. The
TR46/Y121F/T289A mutant isolate showed very high MIC
values to all tested azoles (Monteiro et al., 2018), while the
two TR34/L98H mutant isolates showed high MICs to ITZ
than other azoles. Other azole-resistant A. fumigatus strains
evidenced mutations (F46Y/M172V/N248T/D255E/E427K) are
likely unrelated to azole resistance and were also reported
in susceptible isolates (Howard and Arendrup, 2011). In two
other azole-resistant isolates, no cyp51A gene mutations were
found, suggesting that other mechanisms may be responsible.
The source of mutations for these azole-resistant isolates was
not established, but according to Meis (Meis et al., 2016)
it is probably associated with the environmental route. In
Portugal, strains of mutant resistant A. fumigatus have never
been reported in the environment. However, an increasing
prevalence of isolates with high MICs to azoles has suggested
a selection of cryptic species with a resistance phenotype after
use of antifungal pesticides, such as penconazole (Lago et al.,
2014).
Regardless the possible limitations of this study, such as, the
relatively low number of studied isolates when compared with
reference laboratories (Astvad et al., 2017; Buil et al., 2018), or
the lack of clinical details for all patients as prior azoles exposure,
immunosuppression status or outcome, the results obtained
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may contribute to a better understanding of the presence and
distribution of cryptic species of Aspergillus, their susceptibility
patterns to antifungal drugs, the emergence of resistance to
antifungals and the spread of mutations associated with azoles
resistance.
CONCLUSIONS
The data expressed from this study highlight the presence of
Aspergillus cryptic species in clinical settings, as well as their
resistance to antifungals.
Azole–resistant A. fumigatus is a global issue. The emergence
and spread of resistance mechanisms, associated with treatment
failure in patients with IA, reinforce the need for antifungal
susceptibility surveillance as well as to seek out mutations in
resistance-linked genes. Moreover, it is important to understand
the route of resistance selection in order to implement effective
prevention and control measures.
Most Aspergillus infections, either with cryptic or resistant
strains, affect immunocompromised patients, who are at higher
risk for IA. Such important clinical implications emphasize the
need to identify the strains to the species level and to perform
antifungal susceptibility tests in all Aspergillus spp. isolates
clinically relevant.
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